MYC amplification (50%-70% of HCC patients) drives PD-L1 overexpression and immunosuppression[82], whereas TP53 mutation (~40% of HCC patients) impairs tumor suppressor function, recruits immunosuppressive cells, and remodels the TME immune landscape[83]. The gene discussed is TP53; the disease is hepatocellular carcinoma.